TEST ME BABY, ONE MORE TIME



▲ New York Blood Center

Objectives

 Describe the testing involved when Neonatal alloimmune thrombocytopenia (NAIT) is suspected.

Describe typical results of testing in NAIT cases.

 Explain how clinical presentation of NAIT may not correlate with laboratory test results.



Neonatal Alloimmune Thrombocytopenia

Involves the immune destruction of fetal platelets by maternal antibody

- A mother may become sensitized from an incompatible platelet antigen inherited from the father
- Neonates are at risk for major bleeding complication (intracranial hemorrhage)



Neonatal Alloimmune Thrombocytopenia

- Human Platelet Alloantigens (HPA)
 - HPA antigens 1 11, and 15
 - "a" designated for the high frequency antigens
 - "b" designated for the low frequency antigens
- HPA's are expressed on Glycoproteins (GP's)
 - GP: Ia,IIa, IIb, IIIa, Ibα,β : More on that later
- Most causes of NAIT are due to mismatch of HPA-1a (PL^{A1})
 - 98% of individuals are HPA-1a positive : More on that later



Testing for NAIT


- Maternal and paternal samples needed
 - No sample needed on baby

Maternal sample testing:

- Antibody Screen
- Platelet Bound IgG paternal testing as well
- Crossmatch with paternal platelets neutralize if ABO incompatible
- HPA-1a typing paternal testing as well



- Maternal antibody screen will be positive
 - Solid phase testing may show reactivity with all wells tested – tested against panel of random group O donors





- ELISA testing will help differentiate the antibody based on the reactivity seen with different glycoproteins
 - Examples of different antigens on different glycoproteins are tested
 - Patterns will help differentiate specific antibodies to specific HPA's based on the reactivity seen
- All wells may be positive in solid phase testing, but then singled out via ELISA



GP IIb/IIIa HPA-1a/1a (PIA1) HPA-3a/3a (Baka) HPA-4a/ (Pena) GP IIb/IIIa HPA-1b/1b (PIA2) HPA-3b/3b (Bakb) HPA-4a/ (Pena) GP IIb/IIIa HPA-1a/1a (PIA1) HPA-3b/3b (Bakb) HPA-4a/ (Pena) GP la/lla HPA-5b/5b (Bra) GP la/lla HPA-5a/5a (Brb) GP lb/IX HPA-2a/2b (Koab) Pos and Neg controls HLA Community CLASS I

Blood Center

Save a Life. Right Here, Right Now.

- Another solid phase test can be performed if ELISA testing is unavailable
 - Instead of random platelets, phenotyped platelets are used to help determine the antibody present

Donor ID HLA-A HLA-B PI ^{A1} (HPA-1a) PI ^{A2} (HPA-1b) Pen ^a (HPA-4a) Pen ^b (HPA-4b) Bak ^a (HPA-3a) Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6a) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b) Ko ^b (HPA-2a)	•	Well										
HLA-B PI ^{A1} (HPA-1a) PI ^{A2} (HPA-1b) Pen ^a (HPA-4a) Pen ^b (HPA-4b) Bak ^a (HPA-3a) Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Donor ID										
PI ^{A1} (HPA-1a) PI ^{A2} (HPA-1b) Pen ^a (HPA-4a) Pen ^b (HPA-4b) Bak ^a (HPA-3a) Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6a) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		HLA-A										
PIA2(HPA-1b) Pena(HPA-4a) Penb(HPA-4b) Baka(HPA-3a) Bakb(HPA-3b) Bra(HPA-5b) Brb(HPA-5a) Caa(HPA-6b) Cab(HPA-6a) Gova(HPA-15b) Govb(HPA-15a) Maxa(HPA-9b) Maxb(HPA-9a) Koa(HPA-2b)		HLA-B										
Pen ^a (HPA-4a) Pen ^b (HPA-4b) Bak ^a (HPA-3a) Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)												
Pen ^b (HPA-4b) Bak ^a (HPA-3a) Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		PI ^{A2} (HPA-1b)										
Bak ^a (HPA-3a) Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Pen ^a (HPA-4a)										
Bak ^b (HPA-3b) Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Pen ^b (HPA-4b)										
Br ^a (HPA-5b) Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Bak ^a (HPA-3a)										
Br ^b (HPA-5a) Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Bak ^b (HPA-3b)										
Ca ^a (HPA-6b) Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Br ^a (HPA-5b)										
Ca ^b (HPA-6a) Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Br ^b (HPA-5a)										
Gov ^a (HPA-15b) Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Ca ^a (HPA-6b)										
Gov ^b (HPA-15a) Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Ca ^b (HPA-6a)										
Max ^a (HPA-9b) Max ^b (HPA-9a) Ko ^a (HPA-2b)		Gov ^a (HPA-15b)										
Max ^b (HPA-9a) Ko ^a (HPA-2b)		Gov ^b (HPA-15a)										
Ko ^a (HPA-2b)		Max ^a (HPA-9b)										
·		Max ^b (HPA-9a)										
Ko ^b (HPA-2a)		Ko ^a (HPA-2b)										
		Ko ^b (HPA-2a)										

Typical results of positive NAIT

- Maternal plasma crossmatched with paternal platelets are usually incompatible
- HPA typings will confirm antigen incompatibility, typically seen with HPA-1a



Neonatal Alloimmune Thrombocytopenia

 IRL recommends transfusing random platelets to "soak up" whatever finite number of maternal antibody is circulating

 If requested, HPA-1a negative donors can try to be reached for donation



Received a NAIT workup from hospital A: Baby has a low platelet count


- Maternal sample was nonreactive with two test methods when tested for platelet antibodies
- Both maternal and paternal samples negative for Platelet bound IgG
- Maternal sample (group O) compatible with paternal platelets (group B)
- No HPA-1a typings done since mom was compatible with dad

"The results of these tests do not provide serologic evidence of neonatal immune thrombocytopenia"



Next day, IRL received notification from Hospital A that Baby was still doing poorly:


- Baby not getting a very good bump from plt transfusions
- Baby currently receiving IVIG
- Were transfusing group A and AB platelets, we recommended transfusing group O





Notified that Baby had a bone marrow aspirate done and no megakaryocytes were found

 If megakaryocyte line is only one effected, gives evidence that issue is not an immunologic problem





- The following day, IRL is notified that Baby has been transferred to another hospital "B"
 - Baby's current platelet count on day 2 is 17,000
 - New facility is requesting HPA-1a negative platelets,
 which CBC does not have
 - CBC contacted New York Blood Center, no HPA-1a negative platelets
 - A call list of donors was created to try and get a product
 - Also notified that megakaryocytes <u>were</u> observed in BM....



Side Note

- Why is it so difficult to locate HPA-1a negative donors
 - Being designated with "a", HPA-1a comprises 98% of all donors
 - Leaving 2% of donors compatible
 - Currently, CBC only tests about 50% of donors....
 - Effectively making it twice as hard to find an already difficult to find unit



- Hospital B calls inquiring about the availability of HPA-1a negative platelets – Baby's platelet count not rising after numerous transfusions
 - Unable to find available donors
- Interested in getting HLA and HPA testing on Mother, Father and Baby
 - Requires samples to be sent to New York Blood
 Center, 2 separate labs



- Breakdown of platelet counts:
 - Day two: plt count 17,000 two plt transfusions
 - Day three: plt count 51,000
 - Day four plt count 5,000 one plt transfusion
- Received several more plt transfusions throughout the next two days
- Platelet counts hovered between 30K and 50K




HPA Results

	1a	1b	2 a	2b	3 a	3b	4a	4b	5a	5b	6a	6b	7a	7b	8a	8b	9a	9b	11 a	11b	15 a	15b
Pat	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	+
Mat	0	+	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0
Baby	+/	+	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	+/

HLA Results

	HLA A	HLA-B
Maternal	02:03	07:08
Paternal	01:24	08:35
Baby	01:03	07:08





- Once results were received, consultation with hospital B occurred
 - Just because mom is negative for HPA-1a, doesn't mean she has antibody: test was negative and mom was compatible with dad's platelet
 - But....could be a low titer antibody that is undetectable with our methods: will continue to look for HPA-1a negative donors
 - Hospital B was going to send additional sample out to another facility for further testing



- Hospital B notified the lab that the patient has been discharged with a 66,000 plt count
 - The patient's platelet counts remained stable one week later at 73,000
 - The patient returned one month later with a platelet count of 673,000

- No HPA-1a negative platelets were ever transfused
- No HLA matched platelets were ever requested



Testing from Outside Facility

- Genetic testing was performed on Baby by outside facility
 - A heterozygous variant was observed in gene ITGB3,
 which codes for cell surface proteins on platelets
 - This ITGB3 variant, p.Leu59Pro, has been associated with platelet-type bleeding disorder 16:
 - Premature coronary heart disease
 - Myocardial infarction
 - Hip fracture
 - The ITGB3 variant has also been associated with <u>Neonatal Alloimmune Thrombocytopenia</u>



An Interesting Find



Transfusion. Author manuscript; available in PMC 2013 September 30.

Published in final edited form as:

Transfusion. 2013 June; 53(6): 1309-1318. doi:10.1111/j.1537-2995.2012.03903.x.

Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy

"Findings confirm previous reports that low-avidity HPA-1a antibodies can cause NAIT"



Conclusion

- Testing on maternal sample by two methods showed no antibodies present and XM compatible with paternal plts
 - HPA typing did show mismatch in HPA-1a
- Although no antibodies were detected, that does not supersede Baby's clinical presentation – low titer antibody may not show up
 - Would be worth seeing if HPA-1a negative plts had any better effect
- Platelet-type bleeding disorder 16: a disorder in platelet production



References

- Fung, Mark K., Brenda J. Grossman, Christopher D. Hillyer, and Connie M. Westhoff. *Technical Manual*. Bethesda, MD: American Association of Blood Banks, 2014. Print.
- ITGB3 Gene Genetics Home Reference." *U.S. National Library of Medicine*. National Institutes of Health, n.d. Web. 04 Apr. 2017.
- "NM_000212.2(ITGB3):c.176TC (p.Leu59Pro) Simple Variation Report ClinVar NCBI."
 National Center for Biotechnology Information. U.S. National Library of Medicine, n.d. Web. 04 Apr. 2017.
- Peterson, Julie A., Adam Kanack, Dhirendra Nayak, Daniel W. Bougie, Janice G. Mcfarland, Brian R. Curtis, and Richard H. Aster. "Prevalence and Clinical Significance of Low-avidity HPA-1a Antibodies in Women Exposed to HPA-1a during Pregnancy." Transfusion 53.6 (2012): 1309-318. Web.



Objectives

 Describe the testing involved when Neonatal alloimmune thrombocytopenia (NAIT) is suspected.

Describe typical results of testing in NAIT cases.

 Explain how clinical presentation of NAIT may not correlate with laboratory test results.



QUESTIONS?





▲ New York Blood Center